Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis (TOSCANE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01202500
Recruitment Status : Unknown
Verified September 2010 by Centre Hospitalier Universitaire Dijon.
Recruitment status was:  Recruiting
First Posted : September 16, 2010
Last Update Posted : June 3, 2014
Information provided by (Responsible Party):
Centre Hospitalier Universitaire Dijon

September 15, 2010
September 16, 2010
June 3, 2014
July 2010
July 2010   (Final data collection date for primary outcome measure)
episode of retinochoroiditis [ Time Frame: 2 years ]
Time to the onset of a first episode of retinochoroiditis in the two years of the study (or the onset of a new episode in a child known to already have had at least one lesion), evaluated on a fundus examination using RetCam®.
Same as current
Complete list of historical versions of study NCT01202500 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis
Multicentre, Randomised Study to Determine the Relative Efficacy of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis
Toxoplasmosis is a benign disease in healthy adults, but can be serious in the case of contamination during pregnancy: the parasite can pass through the placental barrier and infect the foetus. The severity of congenital infection varies, but in France, where maternal seroconversions during pregnancy are treated, the manifestations of the disease are often infraclinical at birth and only appear during the first years of life in the form of retinochoroiditis. In order to prevent long-term sequellae, children with confirmed congenital toxoplasmosis (TC) are treated with pyrimethamine combined with either sulfadiazine or sulfadoxine (Fansidar®). The relative efficacy of these two combinations has not yet been evaluated. Moreover, there is no consensus about the duration of the treatment, which varies, in France, from 12 to 24 months depending on the centre. Compared with the duration of parasitaemia in non-treated children, which can persist for up to 4 weeks, these treatments are very long. They are also far longer than the 3 months of treatment, which is in accordance with the World Health Organization (WHO) recommendations, given in Denmark to infants identified as being infected with the parasite during neonatal screening. A one-year treatment was developed in the United States, but it mainly concerns only symptomatic children, given the absence of generalised screening in the United States of America (USA). We have no arguments to justify the use of treatments lasting one year or more in children with asymptomatic or mildly-symptomatic TC. As these treatments carry certain risks, which may be severe, notably with regard to haematological or skin conditions, they have to be supervised closely with biological tests, which adds further constraints for both the children and their parents and increases the cost to health care systems.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Congenital Toxoplasmosis
  • Procedure: reducing treatment to 3 months
    The treatment will be stopped after 3 months
  • Procedure: registered length of treatment
    The treatment procedure will follow the actual recommandation
  • 12 months
    Intervention: Procedure: registered length of treatment
  • Experimental: 3 months
    Intervention: Procedure: reducing treatment to 3 months
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
September 2016
July 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Children meeting the following criteria can be included:

  • Non-severe congenital toxoplasmosis diagnosed in utero or in the first 3 months of life, whether or not in utero treatment was given
  • Treated for 3 months with pyrimethamine combined with sulfamides.
  • age from 3 to 6 months (> 2 months and < 7 months)

Diagnostic criteria for congenital toxoplasmosis:

  • antenatal period: positive Polymerase Chain Reaction (PCR) on the amniotic fluid or positive mouse inoculation for the amniotic fluid
  • postnatal period: presence of specific Immunoglobuline M (IgM) and/or Immunoglobuline A (IgA), positive Western Blot Chemistry (WBC), increase in Immunoglobuline G (IgG).

Severe congenital toxoplasmosis is defined by the presence at birth of at least one of the following signs: > or egal 3 cerebral calcifications, hydrocephaly, microcephaly, convulsions, microphtalmy.

Informed consent must be provided by both parents.

Exclusion Criteria:

Children with the following cannot be included:

  • a severe form of congenital toxoplasmosis
  • inflammatory retinal disease at inclusion or in whom the treatment is contra-indicated (history of hypersensitivity to one of the components, severe renal or hepatic insufficiency, a history of hepatitis linked to treatment with Fansidar®).
Sexes Eligible for Study: All
3 Months to 6 Months   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Centre Hospitalier Universitaire Dijon
Centre Hospitalier Universitaire Dijon
Not Provided
Study Director: Christine BINQUET, MD CHU Dijon
Centre Hospitalier Universitaire Dijon
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP